NOS1 and Parkinson disease: Additionally, the use of nitric oxide synthase (NOS) inhibitors prevents dyskinesia in Parkinson's disease, at least in part via inhibition of glial cell activation and iNOS expression, showing the role of NO in the pathogenesis of PD [106].